Abstract
Background We used summary statistics from previously-published GWAS of systolic and diastolic BP and of hypertension to construct Polygenic Risk Scores (PRS) to predict hypertension across diverse populations.
Methods We used 10,314 participants of diverse ancestry from BioMe to train trait-specific PRS. We implemented a novel approach to select one of multiple potential PRS based on the same GWAS, by optimizing the coefficient of variation across estimated PRS effect sizes in independent subsets of the training dataset. We combined the 3 selected trait-specific PRS as their unweighted sum, called “PRSsum”. We evaluated PRS associations in an independent dataset of 39,035 individuals from eight cohort studies, to select the final, multi-ethnic, HTN-PRS. We estimated its association with prevalent and incident hypertension 4-6 years later. We studied hypertension development within HTN-PRS strata in a longitudinal, six-visit, longitudinal dataset of 3,087 self-identified Black and White participants from the CARDIA study. Finally, we evaluated the HTN-PRS association with clinical outcomes in 40,201 individuals from the MGB Biobank.
Results Compared to other race/ethnic backgrounds, African-Americans had higher average values of the HTN-PRS. The HTN-PRS was associated with prevalent hypertension (OR=2.10, 95% CI [1.99, 2.21], per one standard deviation (SD) of the PRS) across all participants, and in each race/ethnic background, with heterogeneity by background (p-value < 1.0×10-4). The lowest estimated effect size was in African Americans (OR=1.53, 95% CI [1.38, 1.69]). The HTN-PRS was associated with new onset hypertension among individuals with normal (respectively, elevated) BP at baseline: OR=1.71, 95% CI [1.55, 1.91] (OR=1.48, 95% CI [1.27, 1.71]). Association was further observed in age-stratified analysis. In CARDIA, Black participants with high HTN-PRS percentiles developed hypertension earlier than White participants with high HTN-PRS percentiles. The HTN-PRS was significantly associated with increased risk of coronary artery disease (OR=1.12), ischemic stroke (OR=1.15), type 2 diabetes (OR=1.19), and chronic kidney disease (OR=1.12), in the MGB Biobank.
Conclusions The multi-ethnic HTN-PRS is associated with both prevalent and incident hypertension at 4-6 years of follow up across adulthood and is associated with clinical outcomes.
Competing Interest Statement
B Psaty serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. All other co-authors declare no conflict of interest.
Funding Statement
Molecular data for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). Genome sequencing for "NHLBI TOPMed - NHGRI CCDG: The BioMe Biobank at Mount Sinai" (phs001644) were performed at the Baylor College of Medicine Human Genome Sequencing Center and at the McDonnell Genome Institute (3UM1HG008853- WGS 01S2, HHSN26820160003 WGS 3I, HHSN26820160003 WGS 7I). Genome sequencing for "NHLBI TOPMed: Whole Genome Sequencing and Related Phenotypes in the Framingham Heart Study" (phs000974.v4.p3) was performed at the Broad Institute Genomics Platform (3R01HL092577-06S1, 3U54HG003067-12S2). DNA extraction for "NHLBI TOPMed: Genetic Epidemiology Network of Arteriopathy" (phs001345.v2.p1) was performed at the Mayo Clinic Genotyping Core and Genome sequencing was performed at the Broad Institute Genomics Platform (HHSN268201500014C) and the Northwest Genomics Center (3R01HL055673-18S1). Genome sequencing for "NHLBI TOPMed: The Jackson Heart Study" (phs000964.v1.p1) was performed at the Northwest Genomics Center (HHSN268201100037C). Genome sequencing for the "NHLBI TOPMed: The Atherosclerosis Risk in Communities Study" (phs001211.v3.p2) was performed at the Broad Institute Genomics Platform (3R01HL092577-06S1) and the Baylor College of Medicine Human Genome Sequencing Center (HHSN268201500015C, 3U54HG003273-12S2). Genomics sequencing for "NHLBI TOPMed: Cardiovascular Health Study" (phs001368.v2.p1) was performed at the Baylor College of Medicine Human Genome Sequencing Center (3U54HG003273-12S2, HHSN268201500015C, HHSN268201600033I). Genome sequencing for "NHLBI TOPMed: Hispanic Community Health Study/Study of Latinos" (phs001395.v1.p1) was performed at the Baylor College of Medicine Human Genome Sequencing Center (HHSN268201600033I). Genome sequencing for "NHLBI TOPMed: Women's Health Initiative (WHI)" (phs001237.v2.p1) was performed at the Broad Institute of MIT and Harvard (HHSN268201500014C). Genome sequencing for "NHLBI TOPMed: Multi-Ethnic Study of Atherosclerosis" (phs001416.v2.p1) was performed at the Baylor College of Medicine Human Genome Sequencing Center (HHSN268201500015C and 3U54HG003273-12S2) and the Broad Institute for MIT and Harvard (3R01HL092577-06S1). Genome Sequencing for the NHLBI TOPMed: CARDIA Study (phs001612) was performed at the Baylor College of Medicine Human genome Sequencing Center (contract HHSN268201600033I). Core support including centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity QC, and general program coordination were provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed. The Genome Sequencing Program (GSP) was funded by the National Human Genome Research Institute (NHGRI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Eye Institute (NEI). The GSP Coordinating Center (U24 HG008956) contributed to cross-program scientific initiatives and provided logistical and general study coordination. The Centers for Common Disease Genomics (CCDG) program was supported by NHGRI and NHLBI, and whole genome sequencing was performed at the Baylor College of Medicine Human Genome Sequencing Center (UM1 HG008898 and R01HL059367).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
TOPMed freeze 8 WGS data are available by application to dbGaP according to the study specific accessions: ARIC: phs001416, BioMe: phs001644, CFS: phs000954, CHS: phs001368, FHS: phs000974, GENOA: phs001345, HCHS/SOL: phs001395, JHS: phs000964, MESA: phs001211, WHI: phs001237. Study phenotypes are available from dbGaP from study accession: ARIC: phs000090, BioMe: phs001644, CFS: phs000284, CHS: phs000287, FHS: phs000007, GENOA: phs000379, HCHS/SOL: phs000810, JHS: phs000286, MESA: phs000209, WHI: phs000200. Data needed to construct the HTN-PRS will be provided upon paper acceptance as a data supplement, and includes variants, alleles, and weights for each of the Selected CV-PRS based on GWAS of SBP, DBP, and hypertension, mean and SD computed based on the TOPMed-BP dataset, and code to generate the multi-ethnic PRS from plink files using PRSice 2. They are also publicly available on the repository https://github.com/nkurniansyah/Hypertension_PRS.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
TOPMed freeze 8 WGS data are available by application to dbGaP according to the study specific accessions: ARIC: phs001416, BioMe: phs001644, CFS: phs000954, CHS: phs001368, FHS: phs000974, GENOA: phs001345, HCHS/SOL: phs001395, JHS: phs000964, MESA: phs001211, WHI: phs001237. Study phenotypes are available from dbGaP from study accession: ARIC: phs000090, BioMe: phs001644, CFS: phs000284, CHS: phs000287, FHS: phs000007, GENOA: phs000379, HCHS/SOL: phs000810, JHS: phs000286, MESA: phs000209, WHI: phs000200. Data needed to construct the HTN-PRS will be provided upon paper acceptance as a data supplement, and includes variants, alleles, and weights for each of the Selected CV-PRS based on GWAS of SBP, DBP, and hypertension, mean and SD computed based on the TOPMed-BP dataset, and code to generate the multi-ethnic PRS from plink files using PRSice 2. They are also publicly available on the repository https://github.com/nkurniansyah/Hypertension_PRS.
